Cinqair (reslizumab) is an interleukin-5 antagonist monoclonal antibody (IgG4 kappa).
Cinqair is specifically indicated for the add-on maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype.
Cinqair is supplied as a solution for intravenous administration. The recommended dose is 3 mg/kg once every 4 weeks administered by intravenous infusion over 20-50 minutes.
The FDA approval of Cinqair was based on four double-blind, randomized, placebo‑controlled trials in 1,028 adult and adolescent patients with severe asthma on currently available therapies. Cinqair 3 mg/kg or a placebo was administered to patients every four weeks as an add-on asthma treatment. Compared with placebo, patients receiving Cinqair had reductions in asthma exacerbations of up to 59% as well as significant improvement in lung function, symptoms, and asthma-related quality of life.
Adverse effects associated with the use of Cinqair may include, but is not limited to, the following:
Cinqair comes with a black box warning of the potential for anaphylaxis.
Cinqair (reslizumab) is an interleukin-5 antagonist monoclonal antibody (IgG4 kappa). IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils. By inhibiting IL-5 signaling, reslizumab reduces the production and survival of eosinophils; however, the mechanism of reslizumab action in asthma has not been definitively established.
For additional information regarding Cinqair or severe asthma, please visit http://www.cinqair.com/